Freedom of Information request on weekly summary of Yellow Card reporting (FOI 21/650)
Published 29 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-5-july-2021/freedom-of-information-request-on-weekly-summary-of-yellow-card-reporting-foi-21650
8th July 2021
FOI 21/650
Dear
Thank you for your Freedom of Information (FOI) request dated 10th June 2021, where you asked for previous versions of the coronavirus vaccines yellow card weekly summary.
We can confirm that we do hold this information however as we intend to publish the historical versions of the weekly summary on the Yellow Card website we consider that your request is covered by Section 22 of the FOI Act (information intended for future publication) and the information you have asked for is therefore exempt from disclosure.
Section 22 is a qualified exemption which means we have considered whether there is a greater public interest in releasing the information requested or withholding it. We recognise there is strong interest in seeing this data and accept it should not be withheld.
We will be happy to send you a link to the publication once it is available however if there is a specific version that you are looking for, please do let us know.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division